

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000372

International filing date: 04 February 2005 (04.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0402660.5  
Filing date: 06 February 2004 (06.02.2004)

Date of receipt at the International Bureau: 17 March 2005 (17.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



INVESTOR IN PEOPLE


The Patent Office  
 Concept House  
 Cardiff Road  
 Newport  
 South Wales  
 NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *AmBrose*

Dated 28 February 2005





09FEB04 EB71477-3 D00019  
P01/7700 0.00-0402660.5 ACCOUNT CHA

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference P036716GB

2. Patent application number (The Patent Office will fill this part in) 06 FEB 2004 0402660.5

3. Full name, address and postcode of the or of each applicant (underline all surnames) MEDICAL RESEARCH COUNCIL  
20 Park Crescent  
London  
W1B 1AL

00596007001  
Patents ADP number (If you know it)

If the applicant is a corporate body, give the country/state of its incorporation UK

4. Title of the invention HETEROLOGOUS PROTEIN EXPRESSION

5. Name of your agent (if you have one) CARPMAELS & RANSFORD  
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) 43-45 BLOOMSBURY SQUARE  
LONDON  
WC1A 2RA

Patents ADP number (if you know it) 83001

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country	Priority application number (if you know it)	Date of filing (day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application	Date of filing (day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- Otherwise answer NO (See note d) Yes

## Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form	-
Description	24
Claim(s)	3
Abstract	1
Drawing(s)	6

26 2

10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for a preliminary examination and search (Patents Form 9/77)	-
Request for a substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

CARPMAELS & RANSFORD

Date 6th February 2004

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

C.J. MARSHALL

020 7242 8692

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

## HETEROLOGOUS PROTEIN EXPRESSION

All documents cited herein are incorporated by reference in their entirety.

### TECHNICAL FIELD

This invention is in the field of the recombinant expression of proteins in heterologous hosts.

### 5 BACKGROUND ART

Recombinant expression of proteins is of huge importance. For convenience, bacterial hosts such as *E.coli* are typically used. Where bacterial hosts are unsuitable (e.g. where protein glycosylation or other modifications are desired, or where proteins are not expressed for one reason or another) it is common to choose a yeast host, a baculovirus host, or perhaps a cell line derived from a higher  
10 eukaryote, such as a CHO cell line. Plants are also used as recombinant expression hosts.

Although recombinant protein expression is often routine, with off-the-shelf kits being available for general use, many proteins cannot easily be expressed in this way. Bacterial hosts often give insoluble proteins which must be purified and re-folded from inclusion bodies, and do not offer eukaryotic post translational modifications. Yeasts (including *Saccharomyces*) grow poorly when  
15 minimal media are required by the selection systems that are commonly used, and *Pichia* systems [1] are generally useful only for secreted proteins. The baculovirus and CHO systems are cumbersome and expensive, and do not store well by freezing. Plant systems are at an early stage and extensive post-expression processing is required. Moreover, transformed hosts are typically unstable such that it is constantly necessary to impose selective conditions to prevent reversion to a non-transformed  
20 state e.g. by loss of expression plasmids, etc. For these reasons, hosts such as *Saccharomyces* are seen as poor choices for general recombinant expression.

Thus there remains a need for an expression system which avoids the need for expensive reagents, which is genetically stable, which can be frozen well, which can grow quickly and abundantly, and which can produce eukaryotic proteins in a soluble and active form. It is an object of the invention to  
25 provide an improved expression system to address these needs.

### DISCLOSURE OF THE INVENTION

The invention is based on the use of a new class of selection marker in expression vectors.

Selection markers used in prior art systems are often based on including a resistance gene in the vector e.g. an antibiotic resistance gene (e.g. ampicillin resistance, *ampR*), a drug resistance gene  
30 (e.g. neomycin resistance), a herbicide resistance gene (e.g. glyphosate resistance), the HPRT/HAT system, etc. When used with a host that is naturally sensitive to the factor in question, the resistance genes mean that only transformed cells can survive in a medium containing the factor.

- Other selection markers are based on auxotrophic hosts *i.e.* those which require a particular factor in order to survive. Auxotrophic host systems are by far the most commonly used for yeasts [2], usually using *URA3* (for uracil auxotrophs), *LEU2* (for leucine auxotrophs), *TRP1* (for tryptophan auxotrophs) or *HIS3* (for histidine auxotrophs) to complement the mutations in the auxotrophic host and confer prototrophy. The hosts can grow in rich medium, but growth in a medium lacking an essential factor (*e.g.* lacking leucine) leads to cell death. Inclusion of a survival gene (*e.g.* the 2-isopropyl malate dehydrogenase encoded by *LEU2*) on a plasmid ensures that growth in the appropriate minimal medium selects only transformants. On transfer to a rich medium, where selection pressure is absent, auxotrophic hosts tend to lose plasmids encoding the selection markers.
- These prior art selection systems are based on using a growth medium in which only transformants can survive, either by including the lethal factor (transformants are resistant) or by omitting the essential factor (transformants are not auxotrophic). The markers are thus conditional, as the selection pressure applies only under certain conditions. In contrast, the selection markers used according to the present invention are non-conditional *i.e.* the selection pressure is absolute. The markers involved are genes which encode essential survival factors, and loss of the marker gene (*e.g.* by loss of the expression vector) is lethal. By avoiding resistance markers, lethal factors (*e.g.* antibiotics) do not have to be added to culture media, thus simplifying the culture process, reducing costs and avoiding contamination of the expressed protein. By avoiding auxotrophic hosts, cells can be grown in rich media rather than in minimal media, thereby giving much better growth rates.
- Thus the invention provides a cell that expresses both chromosomal genes and extra-chromosomal genes, wherein (a) the expressed extra-chromosomal genes include a gene with an essential function, the expression of which is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not provide that essential function, and (c) the extra-chromosomal genes include a heterologous gene, the expression of which is controlled by a promoter that is functional in the cell. Loss of the extra-chromosomal essential gene is lethal to the cell.

The invention also provides a method for expressing a heterologous gene, comprising the step of growing a cell of the invention in a culture medium. The invention also provides a method for purifying a protein, comprising the steps of: (a) growing a cell of the invention such that it expresses said protein; and (b) purifying the protein. The method may involve the step of: (c) treating the protein with a protease to provide a cleavage product of interest, and this step (c) may follow step (b) or may be an intrinsic part of step (b).

The cell of the invention can be constructed in two steps, as illustrated for yeast in Figure 6 and as described below. The invention uses a starting cell that expresses both chromosomal genes and extra-chromosomal genes, wherein (a) the expressed extra-chromosomal genes include a gene with an essential function, the expression of which is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not provide that essential function, and (c) the extra-chromosomal genes include a conditionally-lethal gene. The invention also provides an

intermediate cell which expresses chromosomal genes, a first set of extra-chromosomal genes and a second set of extra-chromosomal genes, wherein (a) the expressed first and second sets of extra-chromosomal genes both include a gene with the same essential function, the expression of which is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not provide that essential function, (c) the first set of extra-chromosomal genes includes a conditionally-lethal gene, and (d) the second set of extra-chromosomal genes includes both a conditionally-required gene and a heterologous gene.

The invention also provides an extra-chromosomal vector, comprising: (a) an essential gene whose expression is unconditionally required for survival of a cell of interest; (b) a conditionally-required gene to allow selection of host cells which include the extra-chromosomal vector; and (c) a gene encoding a heterologous protein of interest operably linked to a promoter that is functional in the cell of interest.

The invention also provides a method for preparing a cell of the invention, comprising the steps of: (a) obtaining a starting cell, which expresses a conditionally-lethal gene; (b) transforming the starting cell with an extra-chromosomal vector of the invention; (c) selecting transformants which express the vector's conditionally-required gene; and then (d) selecting transformants which lose the conditionally-lethal gene.

The invention alternatively provides a cell which expresses chromosomal genes and extra-chromosomal genes, wherein (a) the expressed extra-chromosomal genes include an essential gene whose expression is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not include said essential gene, and (c) the extra-chromosomal genes include a heterologous gene, the expression of which is controlled by a promoter that is functional in the cell.

### *Essential genes*

The invention is based on the use of genes with essential functions as selection markers. Vectors encoding heterologous products of interest also encode the essential gene. As loss of the essential function is unconditionally lethal, the selection pressure for cells which contain the vector is absolute *i.e.* surviving cells must contain the vector with both the essential gene and the heterologous gene.

The essential gene can be any gene whose loss prevents the growth of cells *e.g.* the loss prevents cell division, prevents mitosis, prevents transcription, prevents translation, or prevents any other metabolic process which is essential for survival in culture. A gene is not an "essential gene" if its expression is required for survival only under certain conditions *e.g.* *ampR* is essential in the presence of ampicillin, but it is not essential under other circumstances, and so *ampR* is not an "essential gene" — its loss is not unconditionally lethal, as a change in growth conditions cannot compensate for the loss of an "essential gene".

The identification of essential genes is straightforward *e.g.* using knockout studies, *etc.* Reference 3 lists various essential genes in *E.coli*, including some which are only conditionally-lethal, and the



profile of the *E.coli* chromosome in reference 4 classifies genes as non-essential or essential. Reference 5 lists various essential genes for yeast, and the EUROSCARF [6] and EUROFAN [7,8] projects have also identified essential genes in yeast. EUROFAN defines an essential gene as one which is "imperative for the vegetative life cycle of a yeast cell grown on rich YPD media at 30°C", and estimated that 16-18% of yeast genes were essential on the basis that "a strain deleted for such a gene cannot grow on YPD at 30°C". As well as these functional studies, genomics (particularly comparative genomics) is often used to identify essential genes [9], and has been applied to *E.coli*, yeasts, *Mycobacterium tuberculosis* [10], etc. A further approach to identifying essential genes is given in reference 11. The DEG "database of essential genes" [12,13] is a further source. The skilled person is thus readily able to identify various genes whose absence cannot be tolerated by a host.

The essential gene is preferably short e.g. with a coding sequence (start codon to stop codon inclusive) of  $\leq 3000$  base pairs (e.g.  $\leq 2500$  bp,  $\leq 2000$  bp,  $\leq 1500$  bp,  $\leq 1250$  bp,  $\leq 1000$  bp, or shorter). The use of short genes is preferred because it reduces the potential for duplication of restriction sites within a vector. If restriction sites are duplicated, however, then codons can be changed to remove the recognition sequence without changing the encoded amino acid(s) or, as an alternative, the vector may be equipped for ligase independent cloning (LIC) as described below.

One advantage of the invention is that high copy numbers of the heterologous gene can be obtained, and this is accompanied by hyper-expression of the essential gene. Thus the essential gene is preferably not lethal when hyper-expressed. To achieve maximum copy number, it is preferred that the essential gene should be required by the host at high levels.

Preferred essential genes include those which encode polypeptides with (a) a molecular weight of less than about 40kDa (e.g.  $< 30$ kDa,  $< 20$ kDa, or  $< 10$ kDa), and/or (b) reasonable cellular abundance as indicated by their codon adaptation indices (CAI [14]) of more than about 0.3. Genes which satisfy these criteria in yeast include: *CDC33*, *COF1*, *EFB1*, *ERG25*, *FBA1*, *GPM1*, *GSP1*, *GUK1*, *HEM13*, *HSP10*, *IPP1*, *NHP2*, *NOP1*, *NOP10*, *NTF2*, *PFY1*, *PSA1*, *RLP24*, *RPB10*, *RPC10*, *RPL5*, *RPL10*, *RPL15A*, *RPL17A*, *RPL18A*, *RPL25*, *RPL28*, *RPL30*, *RPL32*, *RPL33A*, *RPL43A*, *RPP0*, *RPS2*, *RPS3*, *RPS5*, *RPS13*, *RPS15*, *RPS20*, *RPS31*, *SAR1*, *SEC14*, *SMT3*, *SNU13*, *SSS1*, *SUI2*, *TIF11*, *TP11*, *VRG4*, and *YRB1*.

Preferred essential genes include those involved in cell cycle control and/or involved in mitosis.

A preferred essential gene for use with the invention is *MOB1*, whose expression is absolutely required for completion of mitosis and maintenance of ploidy in yeast [15]. The yeast gene is less than 750 bp in length, and hyper-expression of the encoded Mob1 protein is tolerated.

Another preferred essential gene for use with the invention is *Cdc33* (also known as eIF4E), which recognises the 7-methylguanosine-containing cap of mRNA in the first step of mRNA recruitment for translation. The *Cdc33* protein has 212 aa in yeast and is abundant as judged by direct assays and by its CAI index of 0.387. Furthermore, as *CDC33* is a translation factor then increased expression

levels caused by copy number amplification may have a beneficial effect on heterologous protein expression. Over-expression of CDC33 can cause slow growth but this effect can be overcome in a *Δcln3* or *Δcln2* background [16] and should not matter anyway over a typical 4-8 hr induction period.

Another preferred essential gene for use with the invention is *Hsp10*, which is a 10kDa mitochondrial chaperonin in yeast (homologue of *E.coli* GroES) that regulates the Hsp60 chaperonin [17]. Hsp10 is involved in protein folding and sorting in mitochondria.

Other essential genes for use with the invention can be identified empirically *e.g.* by the use of chromosomal knockout techniques to identify lethal knockout mutations, combined with a test for whether the lethal effect can be reversed by supplying a copy of the knocked-out gene on a plasmid.

In cells of the invention, the essential gene is expressed from an extra-chromosomal element rather than from a chromosomal site. Loss of the extra-chromosomal gene results in death of the cell.

The use of an essential gene makes the system inherently stable and so is preferable to the use of a resistance gene for several reasons. For instance: the need for minimal selective media is avoided, thus giving higher growth rates; there is no risk of the final product being contaminated by the resistance molecule *e.g.* antibiotic contamination; and, for cells such as yeasts, the need for expensive anti-microbials is avoided.

As the invention utilises genes that are essential, the absence of that gene from a host's chromosome(s) means that a functional copy of the gene has been lost from the chromosome, to be replaced by the extra-chromosomal gene. It will be understood that the replacement gene need not be precisely the same as the gene which has been lost. Tolerable differences include point mutations that change the gene's sequence without changing the encoded amino acid sequence, point mutations that change the encoded amino acid sequence without functional consequence, the addition of fusion sequences, and the use of a gene that is different from the lost chromosomal copy (*e.g.* from a different species, or even a different type of organism) but which is functionally able to complement that loss. Taking *S.cerevisiae* as an example, therefore, the host could lack an essential gene which is complemented by the corresponding gene from *S.pombe* or from any other eukaryote. The use of a non-identical gene which is less efficient than the native chromosomal gene can further enhance copy number amplification, as described below. However, the use of extra-chromosomal genes which are the same as those found wild-type in the host organism's chromosome is not excluded.

### *Preparing the cell*

Cells of the invention have lost an essential gene on their chromosome(s), but complement that loss using an extra-chromosomal copy of the gene. As loss of an essential gene cannot be tolerated, it is not feasible to make cells of the invention simply by deleting the chromosomal copy and then transforming the mutant cells with a vector encoding the gene, because death means that there is no way of selecting for cells which lack the essential gene. Instead, cells of the invention can be

prepared by means of "plasmid shuffling" [18], involving a transitional stage where cells possess the essential gene in two separate extra-chromosomal forms (e.g. see Figure 6).

The overall shuffling process begins with a mutant cell that lacks a chromosomal copy of an essential gene, but which possesses a replacement copy on a first vector, which vector also contains a conditionally-lethal marker. A second vector of the invention (carrying (a) a further replacement essential gene, (b) a conditionally-essential marker, and (c) a heterologous gene) is then used, and transformants are selected on the basis of the vector's conditionally-selective marker. At this stage the cell contains two extra-chromosomal copies of the essential gene, one on a first vector which contains a negative selection marker and one on a second vector which contains a positive selection marker and a heterologous gene. Loss of either vector leads to retention of the essential gene, but only the second vector is useful for heterologous protein expression. Thus the process then proceeds to eliminate cells which retain the first vector, thereby selecting cells which possess only the second vector. This final selection uses the first vector's conditionally-lethal marker, to yield cells in which the essential gene and the heterologous gene are encoded by the same vector. The overall effect of this process, therefore, is to replace the first vector with the second vector. Cells which lose both vectors lose the essential gene and thus die.

The invention can be performed much more quickly than existing eukaryotic expression systems, such as *Pichia* and baculovirus, and essentially as quickly as with advanced bacterial expression systems. Once the desired DNA fragment is cloned into the plasmid of the invention, a yeast host expressing high levels of the protein can be prepared in less than two weeks.

Overall, the shuffling process involves: (a) a host cell with an inactive chromosomal essential gene, complemented by a 'covering' plasmid which supplies the essential gene and contains a counterselection marker; and (b) an expression plasmid which also supplies an essential gene and contains the heterologous gene of interest (usually under the control of a repressible promoter) plus a selection marker. The shuffling protocol swaps the two plasmids without going via a stage where the extra-chromosomal essential gene is lost.

In *S.cerevisiae* a covering plasmid will generally include the *URA3* counterselection marker, the expression plasmid will include a selection marker (e.g. auxotrophic marker), and the expression of the heterologous product will be controlled by galactose repression of *GAL1-10*. The *URA3* marker advantageously allows selection of starting cells which contain the covering plasmid and also, using FOA, allows counterselection of intermediate cells. Similar considerations apply in *S.pombe*, although the heterologous product may be controlled by thiamine repression of the *nmt1* promoter.

In *E.coli* and other applicable bacteria a covering plasmid may include the *sacB* gene from *B.subtilis*. This gene prevents growth on sucrose, permitting counterselection. Unlike *URA3* the *sacB* gene does not also allow a positive selection and so the covering plasmid will also include a marker such as *kan<sup>R</sup>* for selecting suitable starting cells.

As an alternative to the *sacB* system, the *rpsL* system can be used. Cells carrying the wild type *rpsL* (*Str<sup>sens</sup>*) are sensitive to streptomycin, but many *rpsL* mutations give streptomycin resistance (*Str<sup>res</sup>*). If a cell has both *Str<sup>sens</sup>* and *Str<sup>res</sup>* genes, however, they remain sensitive to streptomycin. A covering plasmid can thus contain wild-type *rpsL* and *kan<sup>R</sup>*. Using a *Str<sup>res</sup>* starting cell and an expression plasmid with *amp<sup>R</sup>* the intermediate cells can be selected based on ampicillin resistance. Loss of the covering plasmid can then be selected based on streptomycin resistance.

The combined use of the *sacB* and *strA* systems in *E.coli* is described in reference 19.

The invention uses a starting cell which expresses chromosomal genes and extra-chromosomal genes, wherein (a) the expressed extra-chromosomal genes include an essential gene whose expression is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not include said essential gene, and (c) the extra-chromosomal genes include a conditionally-lethal gene. Suitable starting cells have been described in the art for various essential genes [e.g. 20,21]. The invention provides a starting cell, characterised in that (i) the cell is a *S.cerevisiae* yeast, and (ii) the essential gene is *MOB1*, *Cdc33* or *Hsp10*.

As an alternative to using a plasmid shuffling approach, it is possible to prepare cells of the invention from diploid cells that are hetero-allelic for an essential gene *i.e.* cells that contain a diploid genome but which express a functional form of the essential gene from only one haploid set of chromosomes. The hetero-allelic cell is transformed with a plasmid encoding both the essential gene and the heterologous gene of interest and, after sporulation, haploids lacking a functional chromosomal gene are selected [22]. This technique is more complicated than plasmid shuffling, but may be preferred if there is frequent recombination between chromosomes and shuffling plasmids.

#### *Extra-chromosomal genes and vectors*

Cells of the invention include extra-chromosomal genes, which are located on an extra-chromosomal vector. Such vectors do not include DNA of the mitochondria, chloroplasts or kinetoplasts (where applicable). Preferred vectors are capable of autonomous replication *i.e.* their copy number can exceed the copy number of the host cell's own chromosome(s). Preferred vectors are non-integrating (unlike the situation with prior art *Pichia* systems). The extra-chromosomal genes will generally be found on a plasmid or in a viral vector.

Plasmids of the invention include an essential gene, such that (a) the plasmid can complement the lack of that gene in a host's chromosome, and (b) loss of the plasmid is lethal to the cell.

Plasmids of the invention also include a heterologous gene.

Plasmids of the invention will usually also include a conditionally-required gene. This gene is not required for survival of a cell of the invention, but may be used during the cell's preparation (see below). Conditionally-required genes allow transformants to be selected under appropriate selective growth conditions, and may confer resistance to an otherwise-toxic substance (*e.g.* an antibiotic

resistance gene, such as *ampR*, *kanR*, *tetR*, *hyg*, etc.; a drug resistance gene, such as *aad*, *ble*, *cat*, *hpt*, *nptII*, *aphII*, *gat*, *pac*, *neoR*, etc.; a herbicide resistance gene, such as *bar*, *pat*, *csr1-1*, *shp*, *epsp*, etc.; and other resistance genes, such as *ble*, *bsd*, *gpt*, *hisD*, *trpB*, *hprt*, *tk*) or treatment (e.g. irradiation, mutagenesis), or may complement an auxotrophic mutation in the host's chromosome (e.g. the *URA3*, *LEU2*, *TRP1*, *HIS3*, *LYS2*, *ADE2*, *ADE3* genes; etc.). A preferred conditionally-required gene is *TRP1*, which can be used to select yeast transformants on the basis of growth in a Trp-free medium.

Other plasmids used in preparing host cells of the invention (e.g. plasmids used to prepare starting cells, and retained in intermediate cells of the invention) include the same essential gene as described above, but include a conditionally-lethal gene for counterselection. Cells containing these plasmids can thus be selectively killed. Typical conditionally-lethal genes encode proteins which convert non-toxic substances into toxic substances, and examples include, but are not limited to: *URA3* (lethal in the presence of 5-fluororotic acid, FOA); *LYS2* (lethal in the presence of  $\alpha$ -aminoadipic acid as the primary nitrogen source); *CAN1* (lethal in the presence of canavanine and absence of arginine); *CYH2* (lethal in the presence of cycloheximide); *Tk* or thymidine kinase (lethal in the presence of ganciclovir or acyclovir); *Cd* or cytosine deaminase (lethal in the presence of 5-fluorocytosine); *Ntr* or nitroreductase (lethal in the presence of CB1954); *sacB* from *B.subtilis* (lethal in the presence of sucrose); *rpsL* and mutant *rpsL* (selection based on streptomycin sensitivity/resistance); etc.

Some conditionally-required genes (for "positive selection") can also be used as conditionally-lethal genes (for "negative selection"), depending on growth conditions. For example, *URA3* is a conditionally-required gene for uracil auxotrophs, but it is lethal when growth occurs in the presence of FOA. Similarly, thymidine kinase offers a salvage pathway in the presence of aminopterin, but is lethal in the presence of acyclovir. Where a process of the invention uses both a conditionally-required gene and a conditionally-lethal gene, however, different genes will usually be used.

As well as (a) the essential gene, (b) the conditionally-required gene, and (c) the optional heterologous gene, plasmids of the invention will typically include one or more of the following elements: (i) an origin of replication functional in a host cell of interest (e.g. functional in yeast, such as an *arsI* element or, more preferably, a  $2\mu$  *ori* element); (ii) a polylinker or multi-cloning site, containing a plurality (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) of restriction sites in the same or, preferably, in different reading frames e.g. see Figure 4; (iii) a transcription termination sequence (e.g. T-*ADHI*, T-*CYC1*, etc.) and/or additional stop codons (TGA, TAA and/or TAG) downstream of one or more (preferably all) of the promoters and their coding sequences in the plasmid; and (iv) a stabilising sequence, such as *stb*. Transcription termination sequences can be included as part of a heterologous insertion rather than as part of a starting vector.

To function as a shuttle vector between eukaryotes and bacteria, thereby simplifying preparative work, the plasmid may also include one or more of: (v) an origin of replication functional in bacteria,

such as the *ColEI* origin of replication; and (vi) an antibiotic resistance marker suitable for selection of bacterial transformants. As an alternative to using bacteria for preparative work, gap repair cloning [23] can be used.

Where a vector is for bacterial expression and is used in a shuffling procedure, an intermediate cell of the invention will include both a covering plasmid and an expression plasmid. The origins of replication in these plasmids should be of different compatibility groups to ensure that they can occupy the same cell during shuffling (*e.g.* one *ColEI*-based plasmid and one P15A-based plasmid).

### ***Heterologous genes***

Plasmids used in cells of the invention, and in intermediate cells, include a heterologous gene *i.e.* a gene not naturally expressed in the organism in which the plasmid is propagated. Transcription of the heterologous gene will generally be under the control of a promoter that is functional in the host cell, as expression of the gene cannot be achieved using a promoter that is inactive in the cell.

The heterologous gene preferably comprises a coding sequence from a eukaryote, more preferably from a higher eukaryote. For example, the heterologous gene may comprise an animal sequence *e.g.* from a mammal, such as a human sequence. As an alternative, the heterologous gene may comprise a coding sequence from a virus (preferably a eukaryotic virus), a parasite, a pathogenic bacterium, *etc.*

Various types of heterologous genes can be used: (a) one type of heterologous gene is a sequence which encodes a polypeptide that is useful during protein purification, and to which a further sequence of interest may be fused to give fusion polypeptides; (b) a second type of heterologous gene is a sequence which encodes a fusion polypeptide, comprising a sequence useful during protein purification, fused to a further sequence of interest; (c) a third type of heterologous gene is a sequence of interest without any fusion sequence. Fusion expression (b) of a protein of interest is typical, but direct expression (c) is also useful. A gene sequence useful during protein expression (a) will not typically be expressed as a protein for its own sake but will be used as a starting material for preparing a fusion construct (b).

Polypeptides commonly used as fusion partners to assist in purification include, but are not limited to: glutathione-S-transferase (GST), purified using immobilised glutathione [24]; poly-histidine tags, purified by IMAC [25]; calmodulin-binding peptide (CBP), purified using immobilised calmodulin; maltose-binding protein (MBP), purified using immobilised amylose; a chitin-binding domain (CBD), purified by binding to chitin; secretory signals; and the Flag epitope (DYKDDDDK) [26], haemagglutinin epitope (YPYDVPDYA, HA-tag), VSV-G epitope, thioredoxin or c-myc epitope (EQKLISEEDL), purified by specific immunoaffinity chromatography. Thus a plasmid of the invention may include a sequence that encodes one of these polypeptides, optionally fused to a further sequence of interest. These two elements may be arranged in either order, N-terminus to C-terminus, but it is typical referred to have the further sequence downstream of (*i.e.* fused to the C-terminus of) the purification sequence.

The ability to express proteins as GST-fusions is an advantage over *Pichia* systems, as GST-fusions in *Pichia* typically fail to bind to immobilised glutathione. The ability to use poly-histidine tags is also an advantage over *Pichia*, where alcohol dehydrogenase protein co-purifies on IMAC columns. The invention avoids these difficulties.

- 5 Where the heterologous sequence is designed for fusing to further sequences, or where it is fused to a further sequence, it is typical to include a protease recognition sequence at the junction between the two (*i.e.* at or near the 3' or 5' end of the heterologous sequence). A protease can then be used to generate the protein of interest without its purification tag. The proteolytic cleavage can take place after purification of the fusion protein or, to simplify purification, can take place while the fusion
- 10 protein is immobilised on an affinity column, allowing the cleaved protein of interest to elute while the purification tag remains immobilised. Protease recognition sites include, but are not limited to: VPR/GS (Thrombin); IEGR (Factor Xa Protease); DDDDK (Enterokinase); ENLYFQ/G (endopeptidase rTEV from tobacco etch virus); and LEVLFQ/GP (human rhinovirus protease 3C). As an alternative to using a protease recognition sequence, a self-cleaving protein can be constructed
- 15 based on inteins [27,28].

Prior to use with the invention, the heterologous gene will be prepared in a form suitable for insertion into a vector of the invention. This may be by digestion of nucleic acid containing the gene, using enzymes that are compatible with the insertion site in the vector of the invention, or by inclusion of addition of suitable sequences during preparation *e.g.* by PCR amplification.

- 20 The insert may be suitable for ligase independent cloning ('LIC' [29-31]). For example, the 5' and 3' regions of the insert may have long (*e.g.*  $\geq 15$  nucleotides) high level of sequence identity to the ends of the linearised vector (usually long sticky ends), thereby facilitating insertion of the sequence into the vector without needing ligase (or phosphatase).

The insert sequence may be directly from a natural gene, or may have been modified in some way

25 *e.g.* to remove introns, to change codon usage, to introduce or remove restriction sites, *etc.*

- The invention has been found to be particularly suitable for expression of proteins which have been difficult to express in existing systems. Lte1 (low temperature essential) [32] is a large yeast protein (>1400 amino acids) which cannot be expressed in *E.coli*, but using the invention is has been successfully expressed in soluble form as a GST-fusion (in both directions, N-terminus to
- 30 C-terminus). Thus the heterologous gene may encode a protein with 300 or more amino acids (*e.g.* 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more), although expression of proteins shorter than 300 amino acids (*e.g.* 200 or fewer amino acids) is not excluded. Yeast proteins Bfa1 and Bub2 are found naturally at low levels and were subject to considerable degradation in *E.coli* expression systems [33], but have now been expressed at high levels in soluble form as GST-fusions. Expression
- 35 of yeast kinases CDC5, CDC15 and CDC28 in *E.coli* gives inactive proteins, but these three proteins have been expressed in active soluble form as GST-fusions in yeasts having chromosomal deletions



of the proteins. Mammalian proteins such as Tpl2 have also been successfully expressed as GST-fusions. Some of these proteins have subsequently been prepared in pure form after thrombin cleavage to remove the GST moiety. Likewise, soluble SARS virus Nsp13 gene product, a putative mRNA Cap1 methyl transferase, has been expressed and cleaved from the GST affinity purification tag using human rhinovirus protease 3C.

Thus the heterologous gene is preferably expressed as a soluble protein, even in fusion form. The production of soluble proteins is an advantage when compared to bacterial expression systems.

Following expression according to the invention, proteins may adopt their native dimeric form in solution. Thus the heterologous gene may encode a protein which naturally forms an oligomer, such as a dimer, trimer, tetramer, pentamer, hexamer, *etc.*

For hetero-oligomeric proteins, it is possible to express multiple heterologous genes from the same plasmid, but it is preferred to use one plasmid per heterologous gene, in which case the invention generally uses one essential gene per monomer *i.e.* the chromosome of a host for expressing a hetero-dimer will have two inactive essential genes, with their functions being complemented by different plasmids. Stoichiometric expression can be achieved if the same promoter is used for each monomer, provided that the plasmids' copy numbers are the same.

The heterologous gene is generally different from the essential gene.

#### *Control of gene expression*

Plasmids for use with the invention include (a) an essential gene, and (b) a conditionally-required gene and/or a conditionally-lethal gene. For expression purposes, plasmids of the invention also include a heterologous gene. Expression of these genes is controlled by upstream promoters. Various promoters may be used, but the invention offers better expression if particular promoters are used.

The essential gene is preferably under the control of a repressible promoter. To increase expression levels, the invention exploits the background level of "leaky" expression driven by such promoters even when they are turned "off" *e.g.* by catabolite repression. As the essential gene is required for the host cell to survive, but the host cell does not have a copy of the essential gene on its own chromosome, there is a selective pressure to increase the plasmid's copy number. As the copy number increases, the overall expression of the essential gene increases such that the combined background expression is adequate for survival.

By repressing expression of the essential gene, therefore, the invention can achieve a high copy number of the plasmid. An increase in copy number also gives increased levels of the heterologous gene, thereby improving expression levels of the protein of interest. The process of the invention may thus include a step of increasing the copy number of a vector to at least 5 (*e.g.* to at least 10, 20, 30, 40, 50 or more). The use of "leaky" low level expression to increase copy number is known [34].



Copy number amplification can be further enhanced by using codons in the essential gene which are non-optimal for the host in question. Where further enhancement of this type is not required, however, the essential gene may be modified for optimum codon usage.

The heterologous gene is preferably under the control of a promoter that is both repressible and inducible. Rather than being used to increase copy number, however, this promoter is used to allow controlled expression of the protein of interest. When there is an increase in copy number of the plasmid, high levels of heterologous protein expression are achieved. It is thus useful to avoid expression of the heterologous gene until a desired time to avoid possible toxic effects of over-expression. For example, if Bfa1 or Clb6 is over-expressed then cells die. Thus the heterologous gene may encode a protein that is potentially toxic to the host during normal growth.

A typical repressible promoter system for use with the invention is based on the *GAL1-10* promoters of Gal1 galactokinase I and Gal10 UDP-glucose 4 epimerase. These are tightly repressed by glucose but highly activated when galactose is the sole carbon source. In *S.cerevisiae*, the dual *GAL1* and *GAL10* promoters are juxtaposed in nature (within the  $P_{GAL1}$  element) and are transcribed in opposite directions, and this arrangement of promoters conveniently allows divergent repression of the essential gene (controlled by one of the pair, in one direction) and the heterologous gene (controlled by the other member of the pair, in the other direction) [35].

Other repressible promoters include, but are not limited to: the repressible acid phosphatase gene promoter (PHO5), which is activated at low inorganic phosphate levels [36,37]; the thiamine-repressible promoter (from *nmt1*), which is repressed by thiamine [38,39]; the metallothionein promoter (from *MTT1*), which is induced by  $Cd^{2+}$  [40]; the copper transport protein promoter (from *CTR3*), which is repressed in the presence of copper ions [41]; a light-switchable system involving a DNA-binding domain fused to phytochrome, a transcription activation domain fused to PIF3, grown in a medium containing phycocyanobilin, with red light being an activator and far-red light being a repressor [42]. In bacteria the IPTG-inducible *lac* promoter can be used.

The heterologous gene and the essential gene may be controlled by separate copies of the same promoter. Expression of the two genes is thus controlled together, although over-expression of the heterologous gene is not generally required for the invention to function.

To express heterologous proteins according to the invention, a promoter will be activated (e.g. by addition of an inducer, or by removal of a repressor). While the expressed extra-chromosomal genes in a cell of the invention must include the essential gene, therefore, the heterologous gene may be expressed or non-expressed depending on prevailing circumstances.

Yeast engages its ubiquitination system to tag many proteins for degradation at the exit from G1 and in the later stages of M phase. This tagging can interfere with the yield of some heterologous proteins in yeast, but can be prevented by arresting cells in early G1 or M phase. Cell cycle arrest can be

achieved in various ways, including the use of  $\alpha$  factor or of cell cycle inhibitors such as nocadazole. Expression methods of the invention may thus involve the use of such reagents.

During expression of the heterologous gene, a yeast may be in diploid or haploid form.

### *Host cells*

5 Because all organisms have essential genes, and the invention is based on the fundamental principle of moving an essential gene from the chromosome onto an extra-chromosomal element so that transformants can be selected, the invention is applicable to all organisms, including prokaryotes and eukaryotes. In particular, the availability of plasmid shuffling protocols for many organisms facilitates the widespread use of the invention. Because bacterial expression systems are already  
10 well-developed, however, the invention's benefits are most immediately useful in eukaryotes, including unicellular eukaryotes (such as yeasts) and multicellular eukaryotes (such as animals and plants). As the use of essential genes as markers avoids the need for antibiotics, however, the invention offers advantages over conventional systems in situations where even traces of antibiotics in the purified expression product cannot be tolerated.

15 The invention is particularly useful for yeasts. Yeast is an inexpensive organism to work with, can be stored easily by freezing, and has an extensive historical background in expression and genetic manipulation, and with the sequencing of the *S.cerevisiae* genome, genomics and proteomics of this organism have been heavily exploited. Many suitable clones and vectors for expression and selection are readily available, and these have been extensively studied and characterised. Furthermore, studies  
20 of the yeast proteome have shown that yeasts are extremely tolerant to the expression of genes in the form of fusion proteins, without loss of solubility or function [43,44].

Preferred yeasts are those which support plasmids and, for assisting in the preparation of cells of the invention, which exist in haploid and diploid forms. Budding yeasts are particularly preferred.

Yeasts include the following genera: *Arthroascus*, *Arxiozyma*, *Bullera*, *Candida*, *Debaryomyces*,  
25 *Dekkera*, *Dipodascopsis*, *Endomyces*, *Eremothecium*, *Geotrichum*, *Hanseniaspora*, *Hansenula*, *Hormoascus*, *Issatchenkia*, *Kloeckera*, *Kluyveromyces*, *Lipomyces*, *Lodderomyces*, *Metschnikowia*, *Pachysolen*, *Pachytichospora*, *Pichia*, *Rhodospiridium*, *Rhodotorula*, *Saccharomyces*, *Saccharomycodes*, *Schizoblastosporion*, *Schizosaccharomyces*, *Schwaniomyces*, *Sporobolomyces*, *Sterigmatomyces*, *Sympodiomyces*, *Taphrina*, *Torula*, *Torulaspora*, *Torulopsis*, *Trichosporon*,  
30 *Yarrowia*, *Zygothansenula*, and *Zygosaccharomyces*. Preferred genera for use with the invention are *Saccharomyces*, *Schizosaccharomyces* and *Pichia*. Common industrial yeast systems include *Hansenula polymorpha*, *Kluyveromyces lactis*, *Yarrowia lipolytica*, *Saccharomyces carlsbergensis*, *Saccharomyces ellipsoideus* and *Candida utilis*, and particularly preferred species for use with the invention are *Saccharomyces cerevisiae* (budding or bakers yeast) and *Schizosaccharomyces pombe*  
35 (fission yeast [45]). Such yeasts are readily available to the skilled person.

Many *E.coli* strains optimised for recombinant protein expression are available e.g. BL21 and its derivatives.

The invention does not utilise wild-type cells as hosts, as the invention relies on the absence of an essential gene from the host's chromosome, with that absence being complemented by an extra-chromosomal copy of the gene. Thus the host's chromosome will be lacking a functional copy of an essential gene. Typically, therefore, the invention will use a host that has a knockout genotype for the essential gene in question. The knockout may remove or disrupt the whole or part of the chromosomal gene, in the regulatory region(s) and/or the coding region(s). Thus remnants of the essential gene may remain in the chromosome, but the overall effect will be that the host's chromosome cannot be transcribed and/or translated to produce the essential gene product in functional form. Knockout of essential genes is known in the prior art [e.g. 20,21] but complementation with extra-chromosomal copies of the genes has been used to study the essential gene itself rather than as a way of selecting for the presence of a different heterologous gene.

Knockout by homologous recombination is a preferred method for obtaining suitable host cells, and in particular knockout by isogenic deletion. Replacement of a chromosomal gene with a marker gene is typical e.g. as a result of homologous recombination to insert an antibiotic resistance gene. Gene inactivation methods such as those disclosed in references 46 and 47 can easily be adapted by the inclusion of covering plasmids encoding an essential gene prior to the inactivation step. Other non-knockout methods of preventing expression of an essential protein include chromatin silencing, antisense and RNA silencing (e.g. RNAi) techniques, although such techniques are not preferred due to their reversible nature and to the difficulty in ensuring that vector-derived genes are not also inactivated. A further way of eliminating the chromosomal gene's function is by mutagenesis of codons encoding critical amino acids e.g. a single Arg-522-His mutation in the *sigA* gene encoding  $\sigma^A$  in *Mycobacterium smegmatis* is lethal, without the need for knockout of the whole coding sequence [48]. Thus the skilled person can readily generate a host cell in which a chosen essential gene has been disabled, either by preventing its expression (either at a transcriptional or translational level) or by allowing its expression but in an inactive form.

In addition to knockout of the essential gene, the host may include further mutations to remove undesirable phenotypes. These mutations may already be present in a starting yeast strain, or they may be introduced.

For example, many host cells express endogenous proteases which degrade heterologous proteins, but which are not essential to viability under laboratory conditions. Deletion of such proteases from the host improves recombinant protein expression. Thus a cell of the invention may include knockout mutations of one or more endogenous proteases. In yeast, deletion of *PEP4* function (the saccharopepsin aspartyl protease [49]) is a preferred mutation. Other proteases which can be knocked out include Prb1, Prc1 and Cps1.

5 The host cell may have mutations in genes responsible to cell wall assembly, such that the cell wall is weakened in order to simplify post-expression processing of cells. Such mutations make cells more fragile, which may not be useful in a general laboratory bench setting, but would be very useful in a specific expression system at an industrial scale where simplification of downstream processing is a higher priority than benchtop resilience.

The host cell may have mutations to prevent slow growth *e.g.* deletion of *cln3* or *cln2* in yeast.

10 The host cell may also include heterologous genes encoding foreign proteins, such as those from non-native metabolic pathways. For example, heterologous glycosyltransferases and other glycosylation enzymes (*e.g.* mannosidases I and II, N-acetylglucosaminyl transferases I and II, uridine 5'-diphosphate (UDP)-N-acetylglucosamine transporter, *etc.*) may be expressed in order to increase the glycosylation repertoire of an expression host [50], and in particular to mimic human glycosylation. Native pathways may be inhibited or knocked out to assist in this approach [51].

### General

15 The term "comprising" means "including" as well as "consisting" *e.g.* a composition "comprising" X may consist exclusively of X or may include something additional *e.g.* X + Y.

The term "about" in relation to a numerical value  $x$  means, for example,  $x \pm 10\%$ .

The word "substantially" does not exclude "completely" *e.g.* a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.

## 20 BRIEF DESCRIPTION OF DRAWINGS

Figure 1 illustrates the construction of starting strains for use with the invention, and figure 2 shows a further development of this process, starting with the strain produced at the end of figure 1.

Figure 3 shows two maps of the pMG1 plasmid, with figure 4 showing its polylinker site.

Figure 5 shows expression from the pMG1 plasmid using glucose (5A) or galactose (5B).

25 Figure 6 shows the plasmid shuffling used in selecting cells of the invention. The yeast cell is shown progressing from starting cell to intermediate cell to a cell useful for heterologous expression of proteins according to the invention.

Figures 7 to 10 show the results of protein expression according to the invention. The lanes were loaded with protein from ~30ml of culture.

## MODES FOR CARRYING OUT THE INVENTION

### Construction of starting yeast strains

Diploid *S.cerevisiae* strains that are heterozygous for *MOB1* (*MOB1/mob1::kan<sup>R</sup>*) are available. Such a strain was obtained and was transformed with a p*URA3* plasmid ("pRS316" [52]) carrying a *Bam*HI-*Eco*RI PCR fragment encompassing the entire *MOB1* coding sequence plus flanking regulatory elements [15]. This strain is *gal2* (has sub-optimal growth on galactose as a sole carbon source) and is *Ura<sup>-</sup>* (requires uracil in growth medium). *Ura<sup>+</sup>* transformants were selected and allowed to sporulate. After germination, haploid *mob1::kan<sup>R</sup>* strains were selected using G418. These cells have lost their chromosomal *MOB1*, but its activity is complemented by the *MOB1<sup>+</sup>* plasmid. These cells were mated with a second haploid strain ("CG379" [53]) which was *MOB1 trp1 GAL2* and the mated diploid cells were then sporulated. Spores which were *trp1 GAL2 mob1::kan<sup>R</sup>* (cannot grow without tryptophan, can grow on galactose, G418 resistant) were selected for G418 resistance and growth on galactose medium. One which was mating type a was designated MGY66 and had the following relevant genotype *MATa mob1::kan<sup>R</sup> trp1 GAL ura3 pURA3-MOB1*. MGY66 is a suitable starting cell for use with the invention, and its overall construction is shown in Figure 1.

As a further development, shown in Figure 2, the *PEP4* gene of this strain was knocked out and replaced with a *LEU2* cassette [54]. The resulting strain is referred to as "MGY70" and is *MATa mob1::kan<sup>R</sup> trp1 GAL pep4::LEU2 ura3 pURA3-MOB1*. The *PEP4* gene encodes an aspartyl protease ("saccharopepsin") which can degrade recombinantly-expressed proteins, but which is not essential for cell survival, and so its deletion can improve yields of stable recombinant proteins.

### Preparation of expression plasmids

Starting with plasmid pESC-URA (Invitrogen™), a *Pvu*II fragment was excised, which contains the divergent, conditional and galactose-inducible yeast *Gal1-10* promoters and yeast *ADH* and *CYC1* terminators. This fragment was used to replace a *Pvu*II fragment of pRS424 [55] to give "pESC-424". An *Eco*RI-*Spe*I fragment encompassing the *MOB1* coding sequence was made by PCR of yeast genomic DNA using the following primers:

Fwd, with *Eco*RI site: CCCGAATTCATGTCTTTTCTACAAAAT

Rev, with *Spe*I site: CCCACTAGTCTACCTATCCCTCAACTCC

The PCR fragment was cloned into the *GAL10* promoter of pESC-424 to give pESC-424-*MOB1*. The same *Eco*RI site was then removed by infilling with Klenow DNA polymerase, to give "pESC-424-*MOB1-ΔEcoRI*". Removal of this *Eco*RI site allowed a unique *Eco*RI site to be later included in a polylinker.

A *Bgl*II-*Xho*I fragment containing a GST coding sequence, a thrombin cleavage site and a polylinker was made by PCR of pGEX-KG [56] and cloned between *Bam*HI and *Xho*I sites of pESC-424-

*MOB1-ΔEcoRI*, to give the plasmid “pMG1” (Figures 3A & 3B). The polylinker site (Figure 4) can receive genes encoding proteins of interest for expression as GST-fusions.

### ***Transformation to express recombinant proteins (Figure 6)***

5 Plasmid pMG1 is grown in *E.coli* and a plasmid DNA miniprep is prepared. Separately, a gene encoding a heterologous protein of interest is prepared which, after restriction enzyme treatment, will have sticky ends that are compatible and in-frame with the polylinker site in pMG1. The two molecules are digested and ligated to give a plasmid encoding the protein of interest in the form of a GST-fusion protein. This plasmid (“pMG1-X”) is transferred into MGY70 yeast by the lithium acetate protocol, and is then selected on a minimal medium lacking tryptophan. As MGY70 is *trp1*,  
10 only transformants survive. Next, the cells are grown on agar with uracil and 1mg/ml 5-fluororotic acid, which selects against *URA3*<sup>+</sup> cells. Surviving cells are those which have lost the *pURA3-MOB1* plasmid, but which have retained pMG1-X as the sole source of *MOB1*.

The final transformants can be grown in rich media (e.g. in YEP medium) without further selection. The cells require uracil to grow, but this is supplied by rich media. The cells can be frozen at this  
15 stage to provide long-term stocks e.g. freezing at –80°C in YEP medium with 20% glycerol.

Expression of the heterologous fusion protein can be induced by switching on the pGAL promoters.

### ***Protein expression and purification***

Yeast cells of the invention contains a heterologous gene under the control of a pGAL promoter. The *MOB1* is also under the control of a pGAL promoter. This arrangement allows a very high copy  
20 number of the pMG plasmid to be achieved prior to expression of the heterologous gene, thereby giving high expression levels. Furthermore, by keeping the heterologous gene in an “off” state at this stage then any possible toxic effects of the heterologous gene are avoided.

Cells need *MOB1* expression to survive. As the *MOB1* gene is under the control of a pGAL promoter, which is repressed when cells are grown on glucose, it would seem on paper that the cells  
25 would die when grown on glucose. As repression is not 100% efficient, however, there is a low-level basal expression from the pGAL promoters (Figure 5A). This basal expression provides low levels of *MOB1* to the growing cells, allowing survival. Moreover, the absolute need for *MOB1* operates as a selection pressure to increase the copy number of pMG1. In the presence of glucose, therefore, the copy number of pMG1 increases to high levels.

30 When expression of the heterologous protein is desired, the cells are transferred to a galactose medium. The absence of glucose and presence of galactose removes repression of the pGAL promoters and expression of the heterologous protein is thus induced (Figure 5B). Furthermore, the recombinant gene is expressed at even higher levels because of the high copy number resulting from the pGAL-controlled *MOB1* selection.

After induction, cells are grown and then harvested. The cell lysate is applied to a glutathione column, which retains the GST-fusion protein. After washing, thrombin is added to the column, leading to elution of the cleaved heterologous protein in pure form.

### *Expression of murine TPL2*

- 5 This transformation/expression/purification process was followed for murine TPL2 protein.

10 A pCDNA3 vector carrying the cDNA of the complete mouse TPL2 coding sequence was used as a PCR template to generate a DNA fragment suitable for cloning into pMGY1. The PCR forwards primer included the first 18 coding bases of TPL2 preceded by a synthetic *Bam*HI site. The *Bam*HI site was designed to so that the TPL2 sequence was in frame with the 3' end of the GST sequence of pMG1. The reverse primer had the last 18 bases of the negative strand in reverse 5'-3' orientation preceded by a synthetic *Xho*I site. The PCR product was prepared for digestion using the Wizard PCR Preps DNA Purification System. The PCR fragment and pMG1 were digested with *Bam*HI and *Xho*I restriction enzymes. The PCR fragment was again purified using the Wizard PCR Preps DNA Purification System. The digested vector was electrophoresed through a 10% agarose TAE buffered gel. Linear plasmid was excised from the gel and purified from the agarose using a GeneClean Kit. Vector and PCR fragments were ligated together by incubation together for 2h. Control ligations were done with no insert DNA.

20 Ligation mixtures were transformed into *E.coli* DH10b. Transformed *E.coli* were selected on L agar containing 20µg/ml ampicillin + 20µg/ml nafcillin. Individual clones were colony purified by restreaking on amp+naf selective medium. Miniprep DNA of individual clones was prepared using the Wizard Plus Minipreps DNA Purification System. Miniprep DNA was digested with *Bam*HI + *Xho*I restriction enzymes to identify clones carrying the ~1.6kb TPL2 coding sequence.

25 The DNA of three potentially positive pMG1-TPL2 clones were transformed into *S.cerevisiae* MGY70 using the lithium acetate procedure. MGY70 transformants with this *TRP1* plasmid were selected by growth at 30°C on minimal agar medium lacking tryptophan. Two individual transformant clones obtained from each miniprep DNA sample were colony purified by re-streaking on agar medium lacking tryptophan. A single colony from each of these plates was streaked onto minimal medium supplemented with 20µg/ml uracil and 1mg/ml FOA. FOA plates were incubated for 2-3 days at 30°C. Single colonies were picked onto fresh FOA plates and grown for a further 2-3 days. In these cells the covering plasmid in MGY70 that provided the essential *MOB1* gene had been replaced by the expression plasmid and its copy of *MOB1*. From this point onwards these cells could be grown on rich medium with no further conditional selection.

35 Examples of the resulting single colonies were next tested for protein expression. However, at this stage it was useful to test whether expression of the cloned gene in toxic as this influences the induction regime for inducible gene expression. Induction of toxic gene products is indicated by

Failure of the cells to grow on rich agar medium with 2% galactose as carbon source. Induction of the potential TPL2 clones was not toxic as judged by this simple test.

Three potential isolates originating from three independent ligation events were tested for expression of TPL2. 50ml overnight cultures were grown at 30°C in rich, YEP, medium with 2% raffinose as carbon source. The cultures were inoculated so that cell density after overnight growth was approximately  $5 \times 10^7$  /ml. The overnight cultures were used to inoculate 500ml of YEP medium supplemented with 2% galactose as carbon source and grown for 6-8h at 30°C. Cells from 50ml and 450ml of culture were harvested by centrifugation, frozen rapidly on dry ice and stored at -80°C. The small pellets were used to check for induced expression of TPL2 while the larger pellets were held in reserve for preparation of Tpl2 for experimental use.

Small pellets were resuspended in 400µl of lysis buffer (50mM Tris-HCl pH 7.5, 250mM NaCl, 1% Nonidet P40, 10% glycerol, 4mM dithiothreitol, 200µg/ml sodium orthovanadate, 10mM NaF, 50mM glycerol-2-phosphate, 1mM PMSF, 'Complete' protease inhibitor (Roche™)). For cell lysis, glass beads, 0.5mm diameter, were added to the meniscus in 2ml screw cap tubes which were then shaken three times 10sec in a RiboLyser apparatus (Hybaid™). Cell lysate was recovered by piecing the base of the tube and followed by centrifugation inside a larger tube. Cell debris and insoluble material was removed by 2x15 min centrifugation at 13000 rpm in a refrigerated micro centrifuge. The cleared lysate was added to 50µl of glutathione sepharose beads which had been pre-equilibrated in 250mM NaCl, 50mM Tris-HCl pH 7.5, 0.2% Nonidet P40. The beads were gently mixed with the lysate on a rotor at 4°C for 1-2h. The beads were washed 5x with 250mM NaCl, 50mM Tris-HCl pH 7.5, 0.2% Nonidet P40, 4mM dithiothreitol. Proteins bound to the glutathione sepharose beads were analysed by SDS-polyacrylamide gel electrophoresis. Protein bands were visualised by staining with coomassie blue (Figure 10).

Large cell pellets were resuspended in lysis buffer (approximately 10ml/1g cells). Cells were lysed with a French pressure cell operating at 20000psi. Cleared lysates were made by centrifugation at 18000g for 2x20 min at 4°C. Large scale affinity purification of GST-TPL2 was essentially as described above except that appropriately increased amounts of reagents were used.

In contrast to the successful expression of TPL2 using the system of the invention, attempts to express the protein in *E.coli* using the pGEX-4t and pET28 plasmids failed. The attempts used the full length protein as well as deletion derivatives lacking the N-terminal 30 residues and/or the C-terminal 70 residues (an oncogenic form). The kinase domain on its own was also tested. In all cases, however, any product which was seen (very little) was heavily degraded, inactive, insoluble or aggregated and was thus of limited use.

Expression was also attempted without success using the Invitrogen™ DES system using the pMT/V5-His vector and S2 *Drosophila* cells.



### ● Expression of other proteins

Essentially similar procedures were used to produce GST-tagged *S.cerevisiae* Cdc16, Bfa1, Bub2, Tem1 and three deletion derivatives of Clb6 that contain the cyclin box domain. With Bfa1 and the Clb6 deletions, over-expression of the expressed proteins was toxic and reduced cell growth during the galactose induction period. To compensate for this, 500ml of overnight culture of these cells in YEP + 2% raffinose was used to inoculate a further 1 litre of YEP medium with a final concentration of 2% galactose. Induction then proceeded for 3-4h before harvesting.

The MOB1 expression system of the invention has been used to express full size Bfa1 (Figure 7), Bub2 (Figure 8), Ltel (Figure 9), Tem1, kinase-dead Cdc15, TPL2 (Figure 10), an oncogenic C-terminally deleted TPL2, TPL2 deleted for 30 N-terminal residues, TPL2 deleted for both 30 N-terminal and 70 C-terminal residues, a kinase dead mutant of TPL2, the SARS virus Nsp13 putative mRNA cap-1 methyltransferase and three deletion derivatives of Clb6. All of these proteins have long histories of being difficult or impossible to produce in other systems but all of them give a GST-fusion product using the MOB1 system of the invention.

Ltel is a large yeast protein (>1400 amino acids). It could not be expressed as a GST-fusion protein using either the pGEX-KG *E.coli* expression system or the pBacPak baculovirus system. In contrast, expression using the MOB1 system of the invention gave high-level expression of the fusion protein in soluble form (Figure 9).

Tem1 is a small Ras-like GTP-binding protein in the regulatory cascade of the mitotic exit network [33,57]. Expression in *E. coli* was attempted with a variety of vectors: pGEX-KG (GST-fusion) and pET28 (hexahistidine tag) did not give useful expression although small quantities of MBP-Tem1 were obtained from a pMAL-c2X vector [33]. Expression of N-terminal fragments (amino acids 1-228 or 1-190) and of a Q79L mutant were also tested in various *E.coli* vectors, with no success. A hexahistidine fusion was tested without success in *P.pastoris* using the pPICZB vector, and the pBakPak8 GST-fusion system also failed in baculovirus. In contrast, expression using the MOB1 system of the invention gave high-level expression of the GST-Tem1 fusion protein in soluble form.

Bub2 is part of a GTPase-activating protein complex involved in the mitotic exit network [33]. Expression of Bub2 was attempted in *E.coli* using the vectors pGEX-KG, pMAL-c2X and pET28 but only the GST-fusion was expressed and this was with large amounts of *E. coli* GroEL chaperone protein. Expression of fragments (amino acids 36-258) and of a GST-Bub2-His<sub>6</sub> protein were also tested in various *E.coli* vectors, with no success. The pPICZαA vector failed in *P.pastoris*, as did the pBakPak8 and pBAC4X vectors in baculovirus. In contrast, expression using the MOB1 system of the invention gave high-level expression of the GST-Bub2 fusion protein in soluble form (Figure 8).

Bfa1 is the other half of the GTPase-activating protein complex (Bfa1/Bub2) [33]. Expression of Bfa1 was attempted in *E.coli* using the vectors pGEX-KG, pGEX-His and pMAL-2c. Only MBP-fusion proteins could be expressed successfully. The pPICZB vector failed in *P.pastoris*, as did the

5 pBakPak8 vector in baculovirus. In contrast, expression using the MOB1 system of the invention gave high-level expression of the GST-Bfa fusion protein in soluble form (Figure 7). GST-Nsp13 expressed from pGEX-6P-2 in *E. coli* was insoluble but soluble GST-Nsp13 was obtained using the MOB1 system. After cleavage of the fusion protein with human rhinovirus protease (PreScission Protease) yields were approximately 1mg Nsp13 /litre of induced cells.

### Hetero-oligomers

10 Yeasts are made with chromosomal deletions of both MOB1 and CDC33. To complement the deletions, yeast are kept alive by a 'covering' plasmid expressing both MOB1 and CDC33 and carrying a *URA3* selective marker. To insert the heterologous gene products, one plasmid is pMG1 as described above and the other is a similar plasmid where (a) MOB1 is replaced by CDC33 and (b) conditional selective marker HIS3 replaces TRP1. To allow separate purification, the second plasmid uses an epitope tag, a hexahistidiny tag or no tag rather than a GST fusion.

15 Heterologous sequences are cloned into the two expression plasmids. The two plasmids are co-transformed into a yeast host, selecting for Trp<sup>+</sup> and His<sup>+</sup> prototrophy. Cells that have lost the *URA3*-covering plasmid are selected on FOA to give a cell capable of expressing two different proteins.

20 In related work, GST-Mob1 was expressed with untagged Dbf2 in *mob1*-deleted cells. Dbf2 is a kinase and Mob1 is an accessory protein required for activity. The divergent *GAL1-10* promoter expressed GST-Mob1 in one direction and untagged Dbf2 in the other. Purification of GST-Mob1 on glutathione sepharose also yielded approximately equimolar amounts of untagged Dbf2, demonstrating how hetero-oligomers can be purified.

### Expression in *Escherichia coli*

An *E.coli* BL21 derivative with good induction and protein stability characteristics is selected.

An essential gene for chromosomal deletion is chosen.

25 A covering plasmid based on pACYC184 is prepared, including: (a) the essential gene, prepared by PCR from *E.coli* genomic DNA and including its natural promoter and regulatory sequences; (b) the conditionally-lethal *sacB* marker to allow counterselection during confirmation of chromosomal deletion and during plasmid shuffling; (c) a P15A replication origin; (d) a chloramphenicol selection marker. The plasmid is transformed into *E.coli* in preparation for deletion of the essential  
30 chromosomal gene.

After introduction of the covering plasmid, the chromosomal copy of the essential gene is replaced with a drug resistance marker using the methods described in reference 46 or 47. The drug resistance marker allows inheritance of the modified gene to be followed. Confirmation that the essential gene is provided by the covering plasmid and not by the chromosome can be provided by attempting to  
35 grow a bacterium in sucrose-based medium.

● An expression plasmid based on pETDuet (Novagen™) is prepared, including: (a) the essential gene; (b) a mammalian, viral or other eukaryotic gene of interest; (c) two multiple cloning sites adjacent to tandem T7lac inducible promoters, with one MCS including a hexa-His tag; (d) a colE1 replication origin, which is compatible with the P15A origin used in the covering plasmid; and (e) an *ampR* gene, which allows the plasmid to be distinguished from the covering plasmid. The two genes (a) and (b) are under the control of the two T7lac promoters. A simpler system uses a normal pET or pGEX vector, with only a single MCS for receiving the mammalian gene; the essential gene with its own promoter is first cloned into a non-MCS site.

10 The expression plasmid is transformed into the *E.coli* to give a bacterium carrying both the covering plasmid and the expression plasmid.

15 Loss of the covering plasmid is then selected by growing bacteria on sucrose. This growth stage can be preceded by a period of growth in the absence of chloramphenicol, in order to provide an opportunity for 'natural' loss of the covering plasmid. After the sucrose counterselection, loss of the covering plasmid is confirmed by checking for chloramphenicol sensitivity. After this confirmation there is no need for further use of antibiotics during growth as the expression plasmid can be maintained by its providing the essential gene rather than by its *ampR* gene. The bacteria can thus be grown through several cultures in order to eliminate any trace of chloramphenicol, thereby giving an antibiotic-free preparation of bacteria which can be used to express the mammalian protein without antibiotic contamination.

20 Bacteria are cultured and then induced under standard condition using IPTG. The mammalian protein is expressed as a GST fusion protein which is then purified using the appropriate affinity column. The native protein is released using thrombin cleavage to give a final purified product.

In a further development, the expression plasmid includes the *oriV*/TrfA replicon system for copy number amplification, as disclosed in reference [58].

25 It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

# REFERENCES (the contents of which are hereby incorporated in full)

- [1] Cereghino & Cregg (2000) *FEMS Microbiology Reviews* 24:45-66.
- [2] Çakar *et al.* (1999) *Biotechnol Letters* 21:611-616.
- [3] <http://magpie.genome.wisc.edu/~chris/essential.html>
- [4] <http://www.shigen.nig.ac.jp/ecoli/pec/index.jsp>
- [5] <http://www.mips.biochem.mpg.de/proj/yeast/tables/essential/lethal.html>
- [6] *European Saccharomyces Cerevisiae Archive For Functional Analysis*. See <http://www.rz.uni-frankfurt.de/FB/fb16/mikro/euroscarf/data/ess.html>
- [7] Dujon (1998) *Electrophoresis* 19:617-624.
- [8] [http://mips.gsf.de/proj/eurofan/eurofan\\_2/b3/](http://mips.gsf.de/proj/eurofan/eurofan_2/b3/)
- [9] Arigoni *et al.* (1998) *Nature Biotechnol* 16:851-856.
- [10] Lamichhane *et al.* (2003) *PNAS USA* 100:7213-7218.
- [11] Haselbeck *et al.* (2002) *Curr Pharm Des.* 8:1155-1172.
- [12] <http://tubic.tju.edu.cn/deg/>
- [13] Zhang *et al.* (2004) DEG, a Database of Essential Genes. *Nucleic Acids Research*, in press
- [14] Sharp & Li (1987) *Nucleic Acids Res* 15:1281-1295.
- [15] Luca & Winey (1998) *Mol Biol Cell* 9:29-46.
- [16] Anthony *et al.* (2001) *J Biol Chem* 276:39645-39652.
- [17] Hohfeld & Hartl (1994) *J Cell Biol* 126:305-315.
- [18] Sikorski & Boeke (1991) *Methods Enzymol* 194:302-318.
- [19] Wang *et al.* (1993) *PNAS USA* 90:7874-7878.
- [20] Nathan & Lindquist (1995) *Mol Cell Biol* 15:3917-3925.
- [21] Elledge & Davis (1988) *Gene* 70:303-312.
- [22] Lisowsky *et al.* (2002) *Mol Biol Cell* 7:2245-55
- [23] Fairhead *et al.* (1996) *Yeast* 12:1439-1457.
- [24] Frangioni & Neel (1993) *Anal Biochem* 210:179-187.
- [25] Gaberc-Porekar & Menart (2001) *J Biochem Biophys Methods* 49:335-360.
- [26] Brizzard *et al.* (1994) *Biotechniques* 16:730-735.
- [27] Chong *et al.* (1997) *Gene* 192:271-281.
- [28] Southworth *et al.* (1999) *Biotechniques* 27:110-120.
- [29] Aslandis *et al.* (1990) *Nucleic Acids Res* 18:6069-6074.
- [30] Haun *et al.* (1992) *Biotechniques* 515-518.
- [31] Stols *et al.* (2002) *Prot Exp & Purif* 25:8-15.
- [32] Keng *et al.* (1994) *Yeast* 10:953-958.
- [33] Geymonat *et al.* (2002) *J Biol Chem* 277:28439-28445.
- [34] Erhart & Hollenberg (1983) *J Bacteriol* 156:625-635.
- [35] Johnston & Davis (1984) *Mol Cell Biol* 4:1440-1448.
- [36] Nakao *et al.* (1986) *Mol Cell Biol* 6:2613-2623.
- [37] Fermiñán & Domínguez (1998) *Appl Environ Microbiol* 64:2403-2408.
- [38] Maundrell (1993) *Gene* 123:127-130.
- [39] Moreno *et al.* (2000) *Yeast* 16:861-872.
- [40] Shang *et al.* (2002) *PNAS USA* 99:3734-3739.
- [41] Labbe & Thiele (1999) *Methods Enzymol* 306:145-153.
- [42] Shimizu-Sato *et al.* (2002) *Nature Biotechnol* 20:1041-1044.

- [43] Huh *et al.* (2003) *Nature* 425:686-691.
- [44] Ghaemmaghami *et al.* (2003) *Nature* 425:737-741.
- [45] Giga-Hama & Kumagai (1999) *Biotechnol Appl Biochem* 30:235-244.
- [46] Datsenko & Wanner (2000) *PNAS USA* 97:6640-6645.
- [47] Link *et al.* (1997) *J Bacteriol* 179:6228-6237.
- [48] Gomez *et al.* (1998) *Mol Microbiol* 29:617-628.
- [49] Ammerer *et al.* (1986) *Mol Cell Biol* 6:2490-2499.
- [50] Hamilton *et al.* (2003) *Science* 301:1244-1246.
- [51] Choi *et al.* (2003) *PNAS USA* 100:5022-5027.
- [52] Sikorski & Hieter (1989) *Genetics* 122:19-27.
- [53] Johnston *et al.* (1990) *Mol Cell Biol* 10:1358-1366.
- [54] Berben *et al.* (1991) *Yeast* 7:475-477.
- [55] Christianson *et al.* (1992) *Gene* 110:119-122.
- [56] Guan & Dixon (1991) *Anal Biochem* 192:262-267.
- [57] Shirayama *et al.* (1994) *Mol Cell Biol* 14:7476-7482.
- [58] Wild *et al.* (2002) *Genome Res* 12:1434-1444.

## CLAIMS

1. A cell that expresses both chromosomal genes and extra-chromosomal genes, wherein (a) the expressed extra-chromosomal genes include a gene with an essential function, the expression of which is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not provide that essential function, and (c) the extra-chromosomal genes include a heterologous gene, the expression of which is controlled by a promoter that is functional in the cell.
2. A method for expressing a heterologous gene, comprising the step of growing the cell of claim 1 in a culture medium.
3. A method for purifying a protein, comprising the steps of: (a) growing the cell of claim 1 by the method of claim 2, such that it expresses said protein; and (b) purifying the protein.
4. The method of claim 3, further comprising the step of: (c) treating the protein with a protease to provide a cleavage product of interest.
5. A cell that expresses both chromosomal genes and extra-chromosomal genes, wherein (a) the expressed extra-chromosomal genes include a gene with an essential function, the expression of which is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not provide that essential function, and (c) the extra-chromosomal genes include a conditionally-lethal gene, wherein the essential gene is *MOB1*, *Cdc33* or *Hsp10*.
6. A cell that expresses chromosomal genes, a first set of extra-chromosomal genes and a second set of extra-chromosomal genes, wherein (a) the expressed first and second sets of extra-chromosomal genes both include a gene with the same essential function, the expression of which is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not provide that essential function, (c) the first set of extra-chromosomal genes includes a conditionally-lethal gene, and (d) the second set of extra-chromosomal genes includes both a conditionally-required gene and a heterologous gene.
7. An extra-chromosomal vector, comprising: (a) an essential gene whose expression is unconditionally required for survival of a cell of interest; (b) a conditionally-required gene to allow selection of host cells which include the extra-chromosomal vector; and (c) a gene encoding a heterologous protein of interest operably linked to a promoter that is functional in the cell of interest.
8. The vector of claim 7, wherein the vector is a plasmid.
9. The vector of claim 7 or claim 8, wherein the conditionally-required gene is a resistance gene.
10. The vector of claim 9, wherein the resistance gene is an antibiotic resistance gene, a drug resistance gene, or a herbicide resistance gene.



11. The vector of claim 7 or claim 8, wherein the conditionally-required gene complement an auxotrophic mutation in the host's chromosome.
12. An extra-chromosomal vector, comprising: (a) an essential gene whose expression is unconditionally required for survival of a cell of interest; (b) a conditionally-lethal gene to allow selective killing of host cells which include the extra-chromosomal vector, wherein the essential gene is *MOB1*, *Cdc33* or *Hsp10*.
13. The vector of any one of claims 7 to 12, comprising one or more of the following elements: (i) an origin of replication functional in a host cell of interest; (ii) a polylinker containing a plurality of restriction sites; (iii) a transcription termination sequence downstream of one or more of the promoters and their coding sequences in the vector.
14. The vector of any one of claims 7 to 13, comprising one or more of: (iii) an origin of replication functional in bacteria; and (iv) an antibiotic resistance marker suitable for selection of bacterial transformants.
15. A method for preparing the cell of claim 1, comprising the steps of: (a) obtaining the cell of claim 5, which includes a conditionally-lethal gene; (b) transforming the cell with the vector of any one of claims 7, 8, 9, 10, 11, 13 or 14, which includes a conditionally-required gene, to give the cell of claim 6; (c) selecting transformants which express the vector's conditionally-required gene; and (d) selecting transformants which lose the conditionally-lethal gene.
16. The cell, method or vector of any preceding claim, wherein the essential gene is a gene whose loss prevents cell division, prevents mitosis, prevents transcription, or prevents translation.
17. The cell, method or vector of any preceding claim, wherein the essential gene has a coding sequence of <3000 base pairs.
18. The cell, method or vector of any preceding claim, wherein the essential gene is not lethal when hyper-expressed.
19. The cell, method or vector of any preceding claim, wherein the essential gene is *MOB1*.
20. The cell, method or vector of any preceding claim, wherein the heterologous gene comprises a sequence from a higher eukaryote or a eukaryotic virus.
21. The cell, method or vector of claim 20, wherein the eukaryote is an animal.
22. The cell, method or vector of any preceding claim, wherein the heterologous gene encodes a fusion protein comprising a first sequence and a second sequence.
23. The cell, method or vector of claim 22, wherein the junction between the first sequence and second sequence includes a protease recognition sequence.

24. The cell, method or vector of claim 23, wherein the protease is thrombin, factor Xa protease, enterokinase, endopeptidase rTEV or human rhinovirus protease 3C.
25. The cell, method or vector of claim 22, wherein the junction between the first sequence and second sequence includes an intein.
- 5 26. The cell, method or vector of any preceding claim, wherein the heterologous gene comprises a sequence encoding glutathione-S-transferase, a poly-histidine tag, a calmodulin-binding peptide, a maltose-binding protein, a chitin-binding domain, or an immunoaffinity epitope.
27. The cell, method or vector of any preceding claim, wherein the heterologous gene encodes a protein which forms oligomers.
- 10 28. The cell, method or vector of any preceding claim, wherein the heterologous gene is expressed as a soluble protein.
29. The cell, method or vector of any preceding claim, wherein expression of the essential gene is controlled by an inducible promoter.
- 15 30. The cell, method or vector of any preceding claim, wherein expression of the heterologous gene is controlled by an inducible promoter.
31. The cell, method or vector of claim 29 or claim 30, wherein the promoter is a repressible promoter.
32. The cell, method or vector of claim 31, wherein the heterologous gene and the essential gene are inducible and/or repressible by the same stimulus.
- 20 33. The cell, method or vector of any preceding claim, wherein expression of the essential gene and/or the heterologous gene is controlled by a galactokinase/UDP-glucose 4 epimerase promoter.
34. The cell, method or vector of any preceding claim, wherein the cell is a eukaryote.
35. The cell, method or vector of claim 34, wherein the eukaryote is a yeast.
- 25 36. The cell, method or vector of claim 35, wherein the yeast is *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe*.
37. The cell, method of vector of any preceding claim, wherein the heterologous gene encodes a Ltel protein, a Bfa1 protein, a Bub2 protein, a CDC5 protein, a CDC15 protein, a CDC28 protein, a Tpl2 protein, a SARS virus Nsp13 protein, or a mRNA Cap1 methyl transferase, protein.




## ● ABSTRACT


Selection markers in prior art systems are based on resistance genes or on complementation of auxotrophic mutations. The requirement for expression of these markers is conditional *e.g.* on the presence of an antibiotic, or on the absence of a nutrient. In contrast, the selection markers used in  
5 this invention are non-conditional, and selection pressure is absolute. The markers involved are genes which encode essential survival factors, such that loss of the marker gene is lethal. Thus the invention provides a cell which expresses chromosomal genes and extra-chromosomal genes, wherein (a) the expressed extra-chromosomal genes include an essential gene whose expression is unconditionally required for survival of the cell, (b) the expressed chromosomal genes do not include  
10 said essential gene, and (c) the extra-chromosomal genes include a heterologous gene. The cells can conveniently be obtained by a plasmid shuffling procedure.

**FIGURE 1****FIGURE 2**






**FIGURE 3A**


Cloned gene

**FIGURE 3B**



**FIGURE 4****FIGURE 5A****FIGURE 5B**




**FIGURE 6**






**FIGURE 7**




**FIGURE 8**





**FIGURE 9**



**FIGURE 10**



— GST-TPL2

